| NOVEN HOLDS ANNUAL MEETING OF SHAREHOLDERS |
NOVEN HOLDS ANNUAL MEETING OF SHAREHOLDERS
Audio
Transcript and Related Slides Available Online
- - - - - - - - - - - - - - - - - - - - - -
MIAMI, FL - June 7, 2000--Noven
Pharmaceuticals, Inc. (Nasdaq:NOVN - news), a leader in the development of transdermal
and transmucosal drug delivery technologies, held its annual meeting of shareholders
yesterday, June 6, in Miami, Florida.
At the meeting, Noven shareholders
voted to elect Sheldon H. Becher, Sidney Braginsky, Rodolfo C. Bryce, John G.
Clarkson, M.D., Lawrence J. DuBow, Steven Sablotsky and Robert C. Strauss as
directors of the Company, and ratified the appointment of Deloitte & Touche
LLP as the Company's independent auditors to audit the Company's financial statements
for 2000.
The annual meeting also
featured a summary of the Company's achievements in 1999 and prospects for 2000
and beyond. An audio transcript of the meeting and related presentation slides
can be accessed on Noven's website at www.noven.com.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery technologies and products. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot™, licensed to Novogyne Pharmaceuticals); combination estrogen/progestin transdermal delivery systems (including CombiPatch™, licensed to Aventis S.A., and Estalis®, licensed to Novartis Pharma AG); and the first transmucosal patch delivery system approved by the FDA (DentiPatch®). With a range of additionalproducts in development, including MethyPatch™ (transdermal methylphenidate system), Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems.
Back